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Summary
Background Patients recruited in randomized controlled trials (RCTs) for biologic
therapies in psoriasis are not fully representative of the real-world psoriasis popu-
lation.
Objectives Firstly, to investigate whether patient characteristics are associated with
being included in a psoriasis RCT. Secondly, to estimate the differences in the
incidence of severe adverse events (SAEs) and the response rate between RCT and
real-world populations of patients on biologic therapies for psoriasis using a stan-
dardization method.
Methods Data from the British Association of Dermatologists Biologics and
Immunomodulators Register (BADBIR) were appended to individual participant-
level data from two RCTs assessing ustekinumab in patients with psoriasis. Base-
line variables were assessed for association of being in an RCT using a multivari-
able logistic regression model. Propensity score weights were derived to reweigh
the registry population so that variables had the distribution of the trial popula-
tion. We measured the C-statistic of the model with trial status as the dependent
variable, and the risk differences in the incidence rate of SAEs in the first year
and Psoriasis Area and Severity Index (PASI) after 6 months in the BADBIR cohort
before and after weighting.
Results In total 6790 registry and 2021 RCT participants were included. The mul-
tivariable logistic regression model had a C-statistic of 0.82 [95% confidence
interval (CI) 0.81–0.83]. The risk differences for the incidence rate of SAEs and
the proportion of patients with PASI < 1.5 were 9.27 (95% CI 3.91–22.5) per
1000 person-years and 0.95 (95% CI 1.98–4.15), respectively.
Conclusions Our results suggest that RCTs of biologic therapies in patients with
psoriasis are not fully representative of the real-world population, but this lack of
external validity does not account for the efficacy–effectiveness gap.
What’s already known about this topic?
• Patients with psoriasis who would not be eligible for randomized controlled trials
(RCTs) investigating biologic therapies have a greater risk of serious adverse events
and lower treatment effectiveness than patients who would have been eligible.
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What does this study add?
• Baseline patient characteristics were shown to be predictive of whether a patient
would have been eligible for enrolment in an RCT for psoriasis biologic therapy.
• We did not find any efficacy–effectiveness gap between the sample representative
of the real-world population of patients with psoriasis and the sample representa-
tive of the RCT population.
• Factors outside of baseline patient characteristics, such as observer effect and higher
adherence in RCTs, may be more influential in any efficacy–effectiveness gap
between trial and real-world populations of patients with psoriasis.
Biologic therapies are widely used for the management of
patients with moderate-to-severe psoriasis. Randomized con-
trolled trials (RCTs) have shown that biologic therapies for
psoriasis have high efficacy and a good safety profile.1
Although RCTs have high internal validity, they are not pow-
ered to investigate rare but potentially serious adverse events
(SAEs). In addition, the exclusion criteria of RCTs limit gener-
alizability. Studies across the different specialties of cardiology,
mental health, rheumatology and oncology indicate that RCT
samples are often highly selected and have a lower risk profile
than real-world populations.2,3 In dermatology, a previous
study in a real-world Spanish psoriasis registry4 found a 2.6-
fold increased risk of SAEs for those patients who would have
been ineligible for entry into an RCT compared with those
who would have been eligible. Our previous work using data
from the British Association of Dermatologists Biologics and
Immunomodulators Register (BADBIR) from the U.K. and Ire-
land corroborated these findings.5 We found a 1.9–2.8-fold
increased risk of SAEs in those who would have been ineligi-
ble compared with those who would have been eligible for
RCTs. In addition, we also found that the ineligible patients
also achieved a smaller improvement in Psoriasis Area and
Severity Index (PASI), a measure of psoriasis disease severity.
These results suggest that there is a gap in the reported effi-
cacy, which represents the effect of the biologic therapy tested
under ideal conditions in an RCT, and the reported effective-
ness, which represents the true effect of the drug under gen-
eral conditions, in real-world populations. This has been
termed the ‘efficacy–effectiveness gap’. These results also sug-
gest a difference in the safety of biologic therapies when used
in RCTs compared with their use in real-world populations.
However, the method of comparing the ineligible against the
eligible is limited by the restricted availability of the full list
of RCT exclusion criteria – a recent research letter found that
only a minority of exclusion criteria from the original proto-
col are listed in publications of phase III trials for biologic
therapies in psoriasis.6 In addition, this method does not pro-
vide insight into the differences between the distribution of
patient characteristics between RCT and real-world populations
within those eligible for the trial. For example, our previous
work showed that women are more likely to develop adverse
events that lead to discontinuation of biologic therapies,7 but
the proportion of female participants in RCTs in psoriasis is
uncharacteristically low for a disease of equal gender ratio.
Model-based standardization methods have increasingly
been used to estimate the gap between RCTs and real-world
populations.8,9 In contrast to common methods of standard-
ization, such as age- or sex-standardized rates, model-based
standardization allows the standardization of a population to
many different covariates.8 A weighting approach, based on
predicting an individual’s probability of being a trial partici-
pant as a function of his or her baseline characteristics, can
achieve this standardization and therefore has the potential to
inform this gap. This in turn can allow clinicians more confi-
dence in interpreting trial findings for the patient in the clinic.
The aims of this study were: (i) to investigate whether
patient characteristics are associated with being in an RCT for
biologic therapies in psoriasis and (ii) to compare the effec-
tiveness and safety results of three biologic therapies used for
the treatment of psoriasis (etanercept, adalimumab and ustek-
inumab) in a real-world population (BADBIR) and the
weighted BADBIR patient population standardized vs. a trial
population (PHOENIX 1 and 2 – trials of ustekinumab for
psoriasis). We also aimed to infer the difference between the
two populations after estimation.
Patients and methods
We used BADBIR as a real-world population and the ustek-
inumab trials PHOENIX 1 and PHOENIX 2 as the representa-
tive psoriasis biologic RCTs.
Real-world population
BADBIR is a prospective pharmacovigilance registry of patients
with psoriasis that was established in 2007 in the U.K. and
Ireland to compare the safety of biologic therapies against
nonbiologic systemic therapies. The design of BADBIR10 and
the baseline patient characteristics11 have been published pre-
viously. As the National Institute for Health and Care Excel-
lence (NICE) recommends that all patients with psoriasis on
biologic therapies should be registered on BADBIR, it is a
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representative sample of the real-world population of such
patients. NICE requires patients with psoriasis to have a PASI ≥
10 and a Dermatology Life Quality Index (DLQI) > 10 to
qualify for treatment with a biologic therapy. We included
adult patients (≥ 18 years old) registering to BADBIR on etan-
ercept, adalimumab or ustekinumab who completed at least
one follow-up as of 1 December 2016.
In BADBIR, patients are recruited and consented during rou-
tine appointments at dermatology centres within 6 months of
initiating or switching to a biologic therapy. Data, including
drug, clinical, anthropometric and comorbid history, are
recorded onto a web-based database by a healthcare profes-
sional. Assessment data from patients are collected 6 monthly
for the first 3 years, then annually thereafter. Medical records
are reviewed for any adverse events since the previous visit,
including SAEs, which are untoward medical occurrences that
are considered to represent a significant hazard to the patient,
namely associated with death, overnight hospitalization,
immediately life-threatening, intravenous antimicrobial admin-
istration, significant loss of function or disability, congenital
malformation or birth defect, or considered to be a medically
important event.
Trial population
PHOENIX 1 and PHOENIX 2 were large phase III RCTs inves-
tigating the use of ustekinumab for the treatment of psoriasis
against placebo.12,13 PHOENIX 1 was a double-blind, placebo-
controlled, multicentre trial performed between December
2005 and September 2007, at 48 sites in the U.S.A., Canada
and Belgium.12 PHOENIX 2 was also a multicentre, double-
blind, placebo-controlled trial, performed at 70 sites in Europe
and North America (Austria, Canada, France, Germany,
Switzerland, U.K. and U.S.A.) between March 2006 and
September 2007.13 Both RCTs evaluated ustekinumab in
patients aged ≥ 18 years with a diagnosis of plaque psoriasis
for 6 months or longer and a baseline PASI of 12 or higher.
Selected exclusion criteria, but not the full list, have been pub-
lished in the respective trial reports.
For the exemplar trial population we included all participants
from PHOENIX 1 and 2 who were randomized. Access to the
individual participant-level data was granted through the Yale
University Open Data Access Project, an academic group serving
as a third party to enable researchers to access clinical trial data
through a structured data request and approval process. These tri-
als were chosen to be the representative trial population because
(i) the time frame for recruitment was close to that of the start
of BADBIR; (ii) ustekinumab is commonly used as a first-line
biologic therapy for the treatment of psoriasis in the U.K.;14 and
(iii) this dataset was available for extraction and combination
with the data from BADBIR.
Statistical analysis
The baseline covariates that were available in both BADBIR
and the trials are listed in Table 1. Due to confidentiality
requirements, the age of trial patients was provided to the
researchers in 5-year categories, as shown in Table 1. Missing
data in both the BADBIR and the trial datasets were accounted
Table 1 The baseline demographics of the trial and registry cohorts
Characteristics
Trial
(n = 2021)
Registry
(n = 6790)
Age category (years), n (%)
< 20 16 (0.8) 80 (1.2)
20–24 76 (3.8) 273 (4.0)
25–29 112 (5.5) 448 (6.6)
30–34 147 (7.3) 667 (9.8)
35–39 251 (12.4) 797 (11.7)
40–44 294 (14.5) 1003 (14.8)
45–49 288 (14.3) 1026 (15.1)
50–54 285 (14.1) 874 (12.9)
55–59 234 (11.6) 691 (10.2)
60–64 155 (7.7) 413 (6.1)
65–69 74 (3.7) 297 (4.4)
70–74 23 (1.1) 129 (1.9)
75–79 7 (0.3) 66 (1.0)
80–85 2 (0.1) 21 (0.3)
> 85 1 (0.0) 5 (0.1)
Female, n (%) 630 (31.2) 2771 (40.8)
Body mass index (kg m2),
mean  SD
31.5  10.4 31.4  10.6
Alcohol (units per week),
mean  SD
3.4  5.8 8.4  14.0
Smoking (cigarettes
per day), n (%)
Nonsmoker 1393 (68.9) 4030 (59.4)
Light (< 10) 192 (9.5) 487 (7.2)
Moderate (10–20) 203 (10.0) 834 (12.3)
Heavy (≥ 20) 233 (11.5) 437 (6.4)
Comorbidities, n (%)
Asthma 163 (8.1) 724 (10.7)
Hypertension 551 (27.3) 1849 (27.2)
Angina 13 (0.6) 184 (2.7)
Myocardial infarction 35 (1.7) 166 (2.4)
Stroke 11 (0.5) 80 (1.2)
Diabetes mellitus 212 (10.5) 637 (9.3)
Depression 300 (14.8) 1539 (22.7)
Psoriatic arthritis 559 (27.7) 1574 (23.2)
Ethnicity, n (%)
Asian 73 (3.6) 310 (4.6)
Black 38 (1.9) 44 (0.6)
White 1871 (92.6) 6240 (91.9)
Other 39 (1.9) 187 (2.8)
Previous therapies,a mean  SD
Systemic therapies 0.9  1.0 1.6  1.0
Biologic therapies 0.6  0.8 0.3  0.6
PASI, mean  SD 19.7  7.6 15.7  7.8
PASI, Psoriasis Area and Severity Index. aPrevious systemic thera-
pies include methotrexate, acitretin, ciclosporin or psoralen–ul-
traviolet A. Previous biologic therapies include adalimumab,
alefacept, efalizumab, etanercept or infliximab in the trial arm,
and the above with the addition of ustekinumab or secukinumab
in the registry arm.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019)
Comparison of registry and trial populations in psoriasis, Z.Z.N. Yiu et al. 3
for using multiple imputation with the generation of 20
imputed datasets using a chained equation approach.
After appending the two datasets into one dataset, we inves-
tigated the strength of association of each covariate in the
determination of whether the individual would be a trial
patient using univariable logistic regression models, and also a
multivariable logistic regression model after multiple imputa-
tion. We calculated propensity scores from the multivariable
logistic regression model, estimating the probability of each
individual patient being a trial participant based on their base-
line background covariates. Standardized mortality ratio
weights were used to reweigh the registry population using
propensity scores (p) so that all variables had the distribution
of the baseline covariates seen in the trial sample (pseudotrial
population). The treated patients were given a weight of 1,
and the untreated patients a weight of p/(1  p), so that the
distribution of the covariates was that of the treated patients.
We then calculated effectiveness and safety outcomes in the
BADBIR cohort before and after weighting. The safety outcome
was the incidence rate of SAEs in the 12 months studied. The
chosen effectiveness outcome was absolute PASI < 1.5 at 6
months, approximately equating to a 90% improvement in PASI
(PASI 90). As overlapping concomitant systemic therapies, lack
of a washout period of nonbiologic systemic therapy and/or the
use of historical PASI are allowed at the onset of biologic treat-
ment in the clinic, the baseline PASI is not reflective of the true
baseline clinical severity of the patient. The use of the absolute
PASI at 6 months mitigates this difference between the trial and
real-world settings. We calculated incidence rate difference, dif-
ference in absolute PASI, incidence rate ratio and risk ratio for
achieving absolute PASI score < 1.5 at 6 months. Next, 95%
confidence intervals (CIs) for these outcomes were estimated
using bootstrap resampling of 1000 replications. Bootstrapping
is a statistical method that mimics the process of sampling from
the underlying population by resampling from the original data
sample with random replacement.
Sensitivity analyses
We planned several sensitivity analyses to investigate how
restricting the BADBIR population to the inclusion or exclu-
sion criteria of the trials impacts on the results. Due to the dif-
ferences in baseline PASI between the two populations listed
above, PASI was not included as a covariate in the main
model, but in model 2 a sensitivity analysis was performed
using only patients with PASI ≥ 12, an inclusion criteria in
the RCTs, and including baseline PASI in the multivariable
logistic regression model. Model 3 restricts the registry popu-
lation to those with no concomitant therapy in the first year.
All analyses were performed with Stata 14.2 (StataCorp,
College Station, TX, U.S.A.).
BADBIR was approved in March 2007 by NHS Research
Ethics Committee North West England, reference 07/MRE08/
9. All patients gave written consent for their participation in
the registry. The protocol for this study was also reviewed and
approved by the BADBIR steering committee and the Yale
University Open Data Access Project (project #2017-1706).
Results
We included 6790 participants from BADBIR and 2021 partic-
ipants from the trials. The baseline covariates common to both
data sources are listed in Table 1. In the BADBIR cohort, 1417
(20.9%) were on etanercept, 3824 (56.3%) were on adali-
mumab and 1549 (22.8%) were on ustekinumab. Age was
available in the trial data in 5-year categories. Eligible previous
systemic nonbiologic therapies were methotrexate, acitretin,
Table 2 The associations (odds ratios and 95% confidence intervals)
of the covariates and trial status from univariable and multivariable
logistic regression models
Univariable
(before multiple
imputation)
Multivariable
(after multiple
imputation)
Age (years)
< 20 0.71 (0.41–1.24) 0.63 (0.34–1.16)
20–24 0.99 (0.75–1.32) 0.83 (0.60–1.14)
25–29 0.89 (0.70–1.14) 0.76 (0.58–1.00)
30–34 0.79 (0.63–0.98) 0.67 (0.52–0.87)
35–39 1.12 (0.93–1.36) 1.04 (0.83–1.30)
40–44 1.04 (0.87–1.26) 0.96 (0.78–1.19)
45–49 Reference Reference
50–54 1.16 (0.96–1.40) 1.12 (0.90–1.38)
55–59 1.21 (0.99–1.47) 1.29 (1.02–1.62)
60–64 1.34 (1.07–1.68) 1.41 (1.09–1.84)
65–69 0.89 (0.67–1.18) 0.92 (0.66–1.29)
70–74 0.64 (0.40–1.01) 0.58 (0.34–1.00)
75–79 0.38 (0.17–0.83) 0.46 (0.20–1.09)
80–85 0.34 (0.08–1.46) 0.40 (0.09–1.80)
> 85 0.71 (0.08–6.12) 0.78 (0.06–9.85)
Body mass index 1.00 (1.00–1.01) 1.00 (0.99–1.00)
Female sex 0.66 (0.59–0.73) 0.53 (0.47–0.60)
Depression 0.60 (0.52–0.68) 0.59 (0.51–0.69)
Diabetes 1.14 (0.97–1.34) 0.97 (0.79–1.19)
Stroke 0.46 (0.24–0.87) 0.45 (0.22–0.93)
Myocardial infarction 0.71 (0.49–1.02) 0.78 (0.50–1.22)
Angina 0.23 (0.13–0.41) 0.19 (0.10–0.36)
Hypertension 1.01 (0.90–1.13) 0.95 (0.82–1.10)
Asthma 0.74 (0.62–0.88) 0.71 (0.58–0.88)
Number of previous
systemics
0.49 (0.46–0.51) 0.42 (0.40–0.45)
Number of previous
biologics
1.83 (1.71–1.96) 2.31 (2.13–2.50)
Psoriatic arthritis 1.27 (1.14–1.42) 1.03 (0.90–1.17)
Previous skin cancer 0.79 (0.54–1.16) 0.97 (0.62–1.53)
Ethnicity
White Reference Reference
Black 2.88 (1.86–4.46) 2.11 (1.26–3.54)
Asian 0.79 (0.61–1.02) 0.53 (0.40–0.71)
Other 0.70 (0.49–0.99) 0.54 (0.37–0.79)
Alcohol 0.93 (0.92–0.94) 0.92 (0.91–0.92)
Smoking (cigarettes per day)
< 10 1.14 (0.95–1.36) 1.41 (1.15–1.73)
10–20 0.70 (0.60–0.83) 0.79 (0.65–0.95)
> 20 1.54 (1.30–1.83) 1.74 (1.42–2.12)
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ciclosporin or psoralen–ultraviolet A, as fumaric acid esters
were not consistently entered as past therapy in the trial popu-
lation. Eligible previous biologic therapies were adalimumab,
alefacept, efalizumab, etanercept or infliximab in both data-
sets, with the addition of ustekinumab and secukinumab in
the registry data. High proportions of missing data for DLQI
in the registry cohort (54.9%) and disease duration in the trial
cohort (87.3%) led to the exclusion of these two covariates.
The amount of missing data for all baseline covariates is pre-
sented in Table S1 (see Supporting Information).
The multivariable logistic regression model had a C-statistic
of 0.82 (95% CI 0.81–0.83), indicating that there was a dif-
ference between the two cohorts, and that the model was able
to separate these two cohorts by the inclusion of these covari-
ates. Patients were significantly more likely to be in the trial
cohort if they were in the age bands of 55–59 or 60–64
years, had been exposed to a higher number of previous bio-
logics, were of black ethnicity, or were in the smoking cate-
gories of < 10 cigarettes per day or > 20 cigarettes per day
(Table 2). Patients were significantly less likely to be in the
trial cohort if they were in the age band of 30–34 years, were
female, had been exposed to a higher number of previous sys-
temic nonbiologics, were of Asian or other ethnic descent (i.e.
not of black or white descent), had higher alcohol intake, or
had the comorbidities of depression, angina or asthma
(Table 2).
After propensity score standardized mortality ratio weight-
ing, the standardized differences for all covariates were within
a magnitude of 0.05, apart from psoriatic arthritis (27.7% in
the trial sample and 31.1% in the pseudotrial sample, stan-
dardized difference 0.08) and the number of previous
biologics (mean 0.57 in the trial sample and 0.62 in the pseu-
dotrial sample, standardized difference 0.07). Both covariates
also had the highest standardized differences among the
covariates for models 2 and 3 in the sensitivity analyses, but
the magnitude of difference was greater.
The standardized mortality ratios for the registry sample
and the pseudotrial sample are presented in Table 3, and the
numbers of patients included in the sensitivity analyses in
Table S2 (see Supporting Information). Weighting had little
effect on the proportion of participants achieving an absolute
PASI < 1.5 at 6 months across all three models. However, the
incidence rates of SAEs were higher in the registry sample
than in the pseudotrial samples across all three models
(Table 3). In the main model, the incidence rate difference
was 9.27 (95% CI 3.91–22.5) per 1000 person-years, trans-
lating to an incidence rate ratio of 1.14 (95% CI 0.91–1.37).
The incidence rate differences and incidence rate ratios for the
sensitivity analyses are also presented in Table 3. These all
suggest a higher incidence rate of SAEs but little difference in
absolute PASI in the registry sample compared with the pseu-
dotrial sample.
Discussion
We show that the distribution of baseline covariates was sys-
tematically different between a real-world and a trial popula-
tion. However, using a novel reweighting and standardization
method, we did not find any efficacy–effectiveness gap
between the sample representative of the RCT population of
patients with psoriasis and the sample representative of the
real-world population. There is a suggestion that the real-
Table 3 Effectiveness and safety outcomes before (registry sample) and after propensity score-based standardized mortality ratio weighting
(pseudotrial sample)
Absolute PASI < 1.5
(~PASI 90) at 6 months
Incidence rate of SAEs per
1000 person-years at 1 year
Model 1 – Full registry cohort
Before weighting 38.0 (36.6–39.5) 75.0 (68.1–82.7)
After weighting 37.1 (33.6–40.6) 65.8 (51.6–83.7)
Absolute risk difference 1.0 (2.0–4.2) 9.3 (3.9–22.5)
Relative risk difference 1.03 (0.94–1.11) 1.14 (0.91–1.37)
Model 2 – Population with starting PASI ≥ 12
Before weighting 37.3 (35.4–39.3) 79.8 (70.6–90.1)
After weighting 38.6 (33.1–44.2) 54.3 (42.8–69.0)
Absolute risk difference 1.3 (6.4–3.8) 25.4 (14.0–37.0)a
Relative risk difference 0.97 (0.84–1.09) 1.47 (1.16–1.78)a
Model 3 – Population without any concomitant therapy during first year of therapy
Before weighting 39.9 (38.2–41.6) 73.5 (66.0–81.9)
After weighting 38.5 (33.8–43.2) 62.2 (48.3–79.9)
Absolute risk difference 1.3 (3.2–5.7) 11.6 (1.4–24.6)
Relative risk difference 1.03 (0.91–1.15) 1.18 (0.93–1.44)
Data are the percentage proportion (95% confidence interval). PASI, Psoriasis Area and Severity Index; PASI 90, 90% improvement in PASI;
SAE, serious adverse event. aStatistically significant result.
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world population had a higher incidence rate of SAEs than the
trial sample, but this was not statistically significant.
However, our results from the sensitivity analyses all sug-
gest a higher point estimate for SAEs with the real-world sam-
ple of patients with psoriasis than in the trial sample. This is
congruent with published literature, which largely compared
those who would not have been eligible for trials against
those who would have been eligible in the real-world popula-
tion.4,5 The magnitude of difference was lower and the differ-
ence was not statistically significant in all but one of the
sensitivity analyses.
The lack of efficacy–effectiveness gap was unexpected. As
we investigated only effectiveness outcomes (and not effi-
cacy), we could not adjust for any differences in adherence
and observer effects that may be present between trial and
real-world populations. In addition, it is unlikely that most of
the covariates we were able to reweigh for that were signifi-
cantly different between the ‘trial’ and ‘real-world’ samples in
Table 2 had any significant impact on the short-term effective-
ness of the biologic therapies. Significant covariates listed in
Table 2 include comorbidities such as depression, stroke, ang-
ina and asthma; alcohol intake; number of previous systemic
therapies; ethnicity and female sex. By contrast, these covari-
ates were more likely to have a significant impact on the
probability of a participant experiencing an SAE. It is also pos-
sible that the missing PASI outcome at 6 months introduced a
systematic bias. This may happen if there was a reason for
PASI being missing at 6 months that is associated with treat-
ment effectiveness, for example patients who were not
responding did not have their PASI measured in clinic because
they were admitted for inpatient treatment.
The major strength of this study is the inclusion and the com-
bination of the individual participant-level data of two impor-
tant data sources for the first time – BADBIR, which is a large
generalizable sample of patients with moderate-to-severe psori-
asis from 153 dermatology centres in the U.K. and Republic of
Ireland, and PHOENIX 1 and 2, two large multinational phase
III RCTs in patients with psoriasis. Detailed data capture in BAD-
BIR allowed inclusion of numerous covariates that were present
in both datasets. We showed that some of these background
participant characteristics were significantly different between a
trial and a real-world psoriasis population, confirming that RCT
inclusion and exclusion criteria and the recruitment process
resulted in a reduction in external validity.
Although we were able to include many baseline covariates,
there may be other covariates important for selection into a
trial, and treatment effect or safety heterogeneity, that could
not be included in the analysis. For instance, the amount of
missing data was too high for DLQI to be included in the
propensity score (Table S1; see Supporting Information).
There may also be uncaptured inherent lifestyle and genetic
participant differences between the U.K. and Ireland-based
BADBIR and the predominantly North American-based PHOE-
NIX 1 and 2 that could partially influence our results. Some
important treatment history covariates, for example whether
the previous biologic therapy had failed due to ineffectiveness
or adverse events, were not available, and this may result in a
decrease in the representativeness of the pseudotrial popula-
tion. The results had large CIs, reflective of the uncertainty in
our estimates given our sample size and our proportion of
missing data.
Our results show that populations of patients with psoriasis
in RCTs are very different from real-world populations. This
reinforces the notion that RCTs have a lower external validity
than real-world studies, and our results may help clinicians
interpret and explain the differences in safety outcomes
between trial results and real-world clinics.
In conclusion, RCTs of biologic therapies in patients with pso-
riasis are not representative of the real-world population. Our
results suggest that the lack of external validity in RCTs for bio-
logic therapies used in patients with psoriasis does not account
for the efficacy–effectiveness gap. It is possible that other factors
such as observer effect and higher adherence in RCTs may be
more influential. Clinicians should utilize data from observational
studies to present a holistic and accurate view of the true benefits
and risks of biologic therapies for psoriasis when counselling
patients prior to the initiation of treatment.
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